CN106727563A - A kind of Western medicine compound for treating fracture - Google Patents
A kind of Western medicine compound for treating fracture Download PDFInfo
- Publication number
- CN106727563A CN106727563A CN201611236039.9A CN201611236039A CN106727563A CN 106727563 A CN106727563 A CN 106727563A CN 201611236039 A CN201611236039 A CN 201611236039A CN 106727563 A CN106727563 A CN 106727563A
- Authority
- CN
- China
- Prior art keywords
- western medicine
- medicine compound
- fracture
- present
- azithromycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Western medicine compound for treating fracture, the Western medicine compound is made up of dextromethorphan hydrobromide and Azithromycin；Wherein, the mass ratio of dextromethorphan hydrobromide and Azithromycin is 0.17~0.22：1；For fracture treatment when, its adult injection dosage be 0.95~1.00mg/kg, administration time for fracture after 6~24 hours.By the test of cure to the modeling animal that fractures, it was found that Western medicine compound of the present invention can reduce the apoptosis of cell, promote the survival of neuron, suppress the formation of glial scar, and significantly improve treatment after animal BBB scoring, show that Western medicine compound of the present invention has significant facilitation for the motor function recovery after fracture.Compared with the common drug methylprednisolone for being clinically used to treat fracture at present, the administration window of Western medicine compound of the present invention is wider, and therapeutic effect is more lasting, and long-term effect is more preferable.
Description
Technical field
The present invention relates to technical field of western medicines, specifically a kind of Western medicine compound for treating fracture.
Background technology
With the development of countries in the world economic level, incidence of fracture is presented the trend for increasing year by year.Fracture refer to due to
Extraneous directly or indirectly factor causes fracture, various motions, sensation and sphincter dysfunction occurs in the corresponding sections of infringement,
The corresponding change of dystonia and pathologic reflex etc..Fracture is the complication of spinal injury most serious, often leads to damage section
Section is with the serious dysfunction of lower limb body.Fracture can not only bring the grievous injury of body and psychology to sufferers themselves, can also be right
Entire society causes huge financial burden.Socie-economic loss caused by fracture, for fracture prevention, treatment and
Rehabilitation has turned into a big problem of current medical field.
The research of the pathogenesis to fracturing shows that fracture is mainly caused by two kinds of mechanism：Primary injury (infringement,
Bleeding etc.) and secondary lesion (inflammatory reaction, ischemia-reperfusion, cell factor etc.).Primary injury passively occurs damaging
After wound in the short time (it is generally acknowledged that in 4 hours), and the nervous lesion for producing is irreversible, and spinal cord injury in rats is one
Kind of cell and molecular level actively adjust process, with invertibity and can be adjusted.
At present, it is the medicine of representative in clinic with methylprednisolone (methylprednisolone, abbreviation methylprednisolone)
Achieve certain curative effect in, but the adverse reaction of medicine and its promptness that uses are so that people are still continuing to look for
The medicine of effect.
The content of the invention
It is an object of the invention to provide a kind of administration window it is wide, consumption is few, effect is lasting, controlling without obvious adverse reaction
Treat the Western medicine compound of fracture.
To achieve the above object, the present invention provides following technical scheme：
A kind of Western medicine compound for treating fracture, is made up of dextromethorphan hydrobromide and Azithromycin；Wherein, hydrobromic acid
The mass ratio of dextromethorphan and Azithromycin is 0.17~0.22：1.
As further scheme of the invention：Described dextromethorphan hydrobromide and the mass ratio of Azithromycin are 0.18
~0.20：1.
As further scheme of the invention：Described dextromethorphan hydrobromide and the mass ratio of Azithromycin are
0.19：1.
Application of the described Western medicine compound in treatment fracture medicine is prepared.
As further scheme of the invention：The adult injection dosage of described Western medicine compound is 0.95~1.00mg/
Kg, administration time is for 6~24 hours after fracture.
As further scheme of the invention：The adult injection dosage of described Western medicine compound is 0.98mg/kg, administration
Time is for 9 hours after fracture.
Compared with prior art, the beneficial effects of the invention are as follows：By the test of cure to the modeling animal that fractures, this is found
Invention Western medicine compound can reduce the apoptosis of cell, promote the survival of neuron, suppress the formation of glial scar, and significantly carry
The BBB scorings of animal after height treatment, show that Western medicine compound of the present invention has for the motor function recovery after fracture significant
Facilitation.Compared with the common drug methylprednisolone for being clinically used to treat fracture at present, the administration of Western medicine compound of the present invention
Window is wider, and therapeutic effect is more lasting, and long-term effect is more preferable.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of Western medicine compound for treating fracture, by dextromethorphan hydrobromide and Azithromycin
Composition；Wherein, the mass ratio of dextromethorphan hydrobromide and Azithromycin is 0.17：1.
Embodiment 2
In the embodiment of the present invention, a kind of Western medicine compound for treating fracture, by dextromethorphan hydrobromide and Azithromycin
Composition；Wherein, the mass ratio of dextromethorphan hydrobromide and Azithromycin is 0.22：1.
Embodiment 3
In the embodiment of the present invention, a kind of Western medicine compound for treating fracture, by dextromethorphan hydrobromide and Azithromycin
Composition；Wherein, the mass ratio of dextromethorphan hydrobromide and Azithromycin is 0.18：1.
Embodiment 4
In the embodiment of the present invention, a kind of Western medicine compound for treating fracture, by dextromethorphan hydrobromide and Azithromycin
Composition；Wherein, the mass ratio of dextromethorphan hydrobromide and Azithromycin is 0.20：1.
Embodiment 5
In the embodiment of the present invention, a kind of Western medicine compound for treating fracture, by dextromethorphan hydrobromide and Azithromycin
Composition；Wherein, the mass ratio of dextromethorphan hydrobromide and Azithromycin is 0.19：1.
In above-described embodiment, the preparation process of the Western medicine compound that described treatment is fractured is：With dextromethorphan hydrobromide
It is active ingredient with Azithromycin, using acceptable technique and auxiliary material in pharmacy, is made in various pharmacies and is subjected to
Peroral dosage form.
In order to verify therapeutic action of the Western medicine compound of the present invention to fracturing, now ground using the fracture model of rat
Study carefully, with the standard drug that clinical treatment is fractured --- methylprednisolone medicine as a comparison, wherein, it is unless otherwise specified, used
Test method is conventional method, medicinal raw material, reagent material used etc. and is commercially available purchase product.
First, therapeutic test of the Western medicine compound of the present invention to fracturing
Using 8 week old female Wistar rats, using New York University (NYU) standard fracture beating device (Impactor
ModelII spinal cord) is hit in the sections of rat chest 10, the animal model of fracture is built.8 hours after damage, respectively by embodiment 1~
With 6.174mg/kg, (dosage is the dose lonvestion system of the dosage × rat by people and people to Western medicine compound obtained in 5
Number 6.3) dosage intraperitoneal injection, 2 weeks are continued to damage once a day, as treatment 1~5 group；8 is small after damage
When, methylprednisolone is administered with the dosage tail vein injection of 30mg/kg, 2 weeks are continued to damage once a day, as compareing 1 group；
8 hours after damage, using physiological saline as compareing 2 groups.8 hours rats of administration are controlled after being damaged using the analysis of BBB point systems
The recovery situation of motor function after treatment, the function of experimental animal after being treated using TUNEL, NF-200 and GFAP dyeing observation each group
The size of Apoptosis, neuronal survival quantity and glial scar after recovery, damage, result of the test is as shown in table 1~2.
The BBB appraisal results of each group of table 1
TUNEL, NF-200 and GFAP dyeing observation result of each group of table 2
| Project | TUNEL | NF-200 | GFAP |
| Treat 1 group | 32000 | 64000 | 55000 |
| Treat 2 groups | 32000 | 65000 | 54000 |
| Treat 3 groups | 31000 | 65000 | 53000 |
| Treat 4 groups | 30000 | 65000 | 52000 |
| Treat 5 groups | 29000 | 66000 | 52000 |
| Compare 1 group | 42000 | 41000 | 72000 |
| Compare 2 groups | 44000 | 37000 | 78000 |
By Tables 1 and 2 it can be seen that：The BBB scorings of 1~5 group for the treatment of are significantly higher than 1~2 group of control, show using this hair
Bright Western medicine compound treatment can remarkably promote the functional rehabilitation after Damage of Rats；The Apoptosis number of the rat of 1~5 group for the treatment of
Amount, GFAP expressions are substantially less than 1~2 group of control, and neuronal quantity is significantly higher than 1~2 group of control, illustrates Western medicine of the present invention
Composition has protective effect to local histocyte after injury, can after injury protect the survival of neuron, promotes nerve
The Regeneration and Repair of unit, while suppressing the formation of chronic phase glial scar, promotes the tissue repair after damaging and functional rehabilitation.
Above-mentioned result of the test shows, compared with 1~2 group of control, acute stage is thin after 1~5 group for the treatment of significantly reduces damage
The necrosis of born of the same parents and apoptosis, promote the survival of neuron and repair；At a specified future date then scope that reduce glial scar, promote rat
Functional rehabilitation after damage.It is indicated above that Western medicine compound of the present invention has the curative effect for determining to fracture, wherein embodiment 5 is made
The Western medicine compound therapeutic effect for obtaining is optimal.
2nd, when different time is administered, Western medicine compound obtained in embodiment 5 is contrasted with the therapeutic effect of methylprednisolone
When being administered by different time, the Comparison of therapeutic of Western medicine compound obtained in embodiment 5 and methylprednisolone determines this hair
Validity of the bright Western medicine compound for clinical treatment of fracturing.
8 week old female Wistar rats are divided into three groups (every group 30), are fractured using New York University (NYU) standard and hit
Device (Impactor ModelII) the sections of rat chest 10 hit spinal cord, choose strike after at once (0 hour), 3 hours, 6 hours,
3 groups of animals are carried out physiological saline, methylprednisolone and implementation by 9 hours, 12 hours, 18 hours, 24 hours seven administration times respectively
Western medicine compound of the present invention obtained in example 5 is treated and continues 2 weeks, observes the recovery situation of rat, the result of the test such as institute of table 3~4
Show.
The each group NF200 dyeing observation results of the different time of table 3 administration
| Project | Western medicine compound treatment group of the present invention | Methylprednisolone treatment group | Saline control group |
| 0 hour | 17 | 116 | 1.1 |
| 3 hours | 40 | 39 | / |
| 6 hours | 119 | 32 | / |
| 9 hours | 142 | 29 | / |
| 12 hours | 130 | 20 | / |
| 18 hours | 56 | 12 | / |
| 24 hours | 22 | 7 | / |
The each group GFAP dyeing observation results of the different time of table 4 administration
Be can be seen that by table 3 and table 4：In administration in 9 hours after Damage of Rats, Western medicine compound treatment group of the present invention rat
Neuronal quantity be significantly higher than the neuronal quantity of methylprednisolone treatment group rat, and methylprednisolone treatment is brighter in early efficacy
It is aobvious, but with the postponement of administration time, its effect is significant declines；In administration in 9 hours after Damage of Rats, Western medicine combination of the present invention
Thing treatment group is most notable to the inhibitory action of glial scar, and its inhibition to glial scar is significantly higher than methylprednisolone group.
To sum up, administration in 9 hours can preferably play therapeutic effect of the Western medicine compound of the present invention to fracture after damage.
To sum up, methylprednisolone is more significant in the therapeutic effect for damaging early stage, but its curative effect is reduced with the postponement of administration time,
Administration window is narrower, and long-term effect is limited；And the therapeutic effect of Western medicine compound of the present invention is more lasting, the administration window phase is more
Width, late result is notable.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (6)
1. a kind of Western medicine compound for treating fracture, it is characterised in that be made up of dextromethorphan hydrobromide and Azithromycin；Its
In, the mass ratio of dextromethorphan hydrobromide and Azithromycin is 0.17~0.22：1.
2. the Western medicine compound that treatment according to claim 1 is fractured, it is characterised in that described dextromethorphan hydrobromide
It is 0.18~0.20 with the mass ratio of Azithromycin：1.
3. the Western medicine compound that treatment according to claim 2 is fractured, it is characterised in that described dextromethorphan hydrobromide
It is 0.19 with the mass ratio of Azithromycin：1.
4. the application according to any described Western medicine compound of claims 1 to 3 in treatment fracture medicine is prepared.
5. application of the Western medicine compound according to claim 4 in treatment fracture medicine is prepared, it is characterised in that described
Western medicine compound adult injection dosage be 0.95~1.00mg/kg, administration time for fracture after 6~24 hours.
6. application of the Western medicine compound according to claim 5 in treatment fracture medicine is prepared, it is characterised in that described
Western medicine compound adult injection dosage be 0.98mg/kg, administration time for fracture after 9 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611236039.9A CN106727563A (en) | 2016-12-28 | 2016-12-28 | A kind of Western medicine compound for treating fracture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611236039.9A CN106727563A (en) | 2016-12-28 | 2016-12-28 | A kind of Western medicine compound for treating fracture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727563A true CN106727563A (en) | 2017-05-31 |
Family
ID=58924618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611236039.9A Pending CN106727563A (en) | 2016-12-28 | 2016-12-28 | A kind of Western medicine compound for treating fracture |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727563A (en) |
-
2016
- 2016-12-28 CN CN201611236039.9A patent/CN106727563A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015024420A1 (en) | Local anesthesia pain-relieving time-delay agent | |
| Uchiyama et al. | Neuromodulation using intrathecal baclofen therapy for spasticity and dystonia | |
| CN106727563A (en) | A kind of Western medicine compound for treating fracture | |
| CN104435544A (en) | Traditional Chinese medicine oral liquid for treating leukemia through being cooperated with chemotherapy and preparation method thereof | |
| CN110325214A (en) | Low-dose drugs for preventing and treating neure damage combine | |
| CN106511359A (en) | Western medicine mixture for treating spinal cord injury, and application thereof | |
| CN104383453B (en) | Treat the Chinese medicine of craniocerebral injury manic disorder | |
| CN106580974A (en) | Western medicine composition for treating spinal cord injury, and application of composition | |
| CN101590114B (en) | Medicament for treating multiple sclerosis and preparation method thereof | |
| CN104435437B (en) | A kind ofly treat Chinese medicine of the concurrent glossopharyngeal neuralgia of trigeminal neuralgia and preparation method thereof | |
| CN104324188A (en) | Traditional Chinese medicine composition for treating childhood tourette syndrome and preparation method thereof | |
| CN103735676B (en) | A kind of compound Chinese medicinal preparation for the treatment of traumatic injury and its preparation method and application | |
| CN106511987A (en) | Western medicine compound for treating fracture | |
| Foroughi | The miracle of Lidocaine: Second look with cellular and molecular perspectives | |
| CN106852932A (en) | A kind of medicine for treating cirrhotic ascites | |
| CN100352477C (en) | Wound healing medicine | |
| CN106491614A (en) | A kind of Western medicine for treating spinal cord injury is combined and purposes | |
| CN106580969A (en) | Western medicine compound for treatment of spinal cord injury and use thereof | |
| CN103405485A (en) | Chinese medicine injection for treating allergic rhinitis | |
| CN106727557A (en) | It is a kind of to treat Western medicine compound of esophagitis and application thereof | |
| CN104524266A (en) | Preparation method of ion introduction agent for treating children hyperthyroidism | |
| CN116440232A (en) | Traditional Chinese medicine composition for preventing and treating numbness and pain of hands and feet related to tumors | |
| CN114344363A (en) | Traditional Chinese medicine composition for preventing and treating tumors and related treatment posthand and foot numbness and pain | |
| CN108653614A (en) | A kind of drug and preparation method thereof for treating tumour | |
| CN103690644A (en) | Traditional Chinese medicine preparation for promoting fracture rehabilitation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |
|
| WD01 | Invention patent application deemed withdrawn after publication |